PMID- 21907762 OWN - NLM STAT- MEDLINE DCOM- 20120322 LR - 20231105 IS - 1873-7544 (Electronic) IS - 0306-4522 (Linking) VI - 198 DP - 2011 Dec 15 TI - Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. PG - 252-73 LID - 10.1016/j.neuroscience.2011.08.052 [doi] AB - Huntington's disease (HD) is a progressive, fatal neurological condition caused by an expansion of CAG (glutamine) repeats in the coding region of the Huntington gene. To date, there is no cure but great strides have been made to understand pathophysiological mechanisms. In particular, genetic animal models of HD have been instrumental in elucidating the progression of behavioral and physiological alterations, which had not been possible using classic neurotoxin models. Our groups have pioneered the use of transgenic HD mice to examine the excitotoxicity hypothesis of striatal neuronal dysfunction and degeneration, as well as alterations in excitation and inhibition in striatum and cerebral cortex. In this review, we focus on synaptic and receptor alterations of striatal medium-sized spiny (MSNs) and cortical pyramidal neurons in genetic HD mouse models. We demonstrate a complex series of alterations that are region-specific and time-dependent. In particular, many changes are bidirectional depending on the degree of disease progression, that is, early vs. late, and also on the region examined. Early synaptic dysfunction is manifested by dysregulated glutamate release in striatum followed by progressive disconnection between cortex and striatum. The differential effects of altered glutamate release on MSNs originating the direct and indirect pathways is also elucidated, with the unexpected finding that cells of the direct striatal pathway are involved early in the course of the disease. In addition, we review evidence for early N-methyl-D-aspartate receptor (NMDAR) dysfunction leading to enhanced sensitivity of extrasynaptic receptors and a critical role of GluN2B subunits. Some of the alterations in late HD could be compensatory mechanisms designed to cope with early synaptic and receptor dysfunctions. The main findings indicate that HD treatments need to be designed according to the stage of disease progression and should consider regional differences. CI - Copyright (c) 2011 IBRO. Published by Elsevier Ltd. All rights reserved. FAU - Raymond, L A AU - Raymond LA AD - Department of Psychiatry and Brain Research Centre, University of British Columbia, Vancouver, Canada. FAU - Andre, V M AU - Andre VM FAU - Cepeda, C AU - Cepeda C FAU - Gladding, C M AU - Gladding CM FAU - Milnerwood, A J AU - Milnerwood AJ FAU - Levine, M S AU - Levine MS LA - eng GR - R01 NS041574/NS/NINDS NIH HHS/United States GR - R01 NS041574-10/NS/NINDS NIH HHS/United States GR - MOP 12699/CAPMC/CIHR/Canada GR - NS41574/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20110827 PL - United States TA - Neuroscience JT - Neuroscience JID - 7605074 RN - 0 (Receptors, N-Methyl-D-Aspartate) SB - IM MH - Animals MH - Corpus Striatum/*pathology MH - Disease Models, Animal MH - Humans MH - Huntington Disease/*pathology/*physiopathology MH - Mice MH - Receptors, N-Methyl-D-Aspartate/*metabolism MH - Synapses/*physiology MH - Time Factors PMC - PMC3221774 MID - NIHMS321948 EDAT- 2011/09/13 06:00 MHDA- 2012/03/23 06:00 CRDT- 2011/09/13 06:00 PHST- 2011/05/25 00:00 [received] PHST- 2011/07/31 00:00 [revised] PHST- 2011/08/22 00:00 [accepted] PHST- 2011/09/13 06:00 [entrez] PHST- 2011/09/13 06:00 [pubmed] PHST- 2012/03/23 06:00 [medline] AID - S0306-4522(11)00994-8 [pii] AID - 10.1016/j.neuroscience.2011.08.052 [doi] PST - ppublish SO - Neuroscience. 2011 Dec 15;198:252-73. doi: 10.1016/j.neuroscience.2011.08.052. Epub 2011 Aug 27.